SCHEMBL25385011

SCHEMBL25385011

COC(=O)C(C)(C)c1ccc(C2OCCO2)c(OCc2ccc(OC)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ HPGD P15428 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ SMPD1 P17405 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ MTNR1A P48039 1/20 0.38
▸ MTNR1B P49286 1/20 0.38
▸ PPARA Q07869 4/20 0.38
▸ PPARG P37231 2/20 0.38
▸ PPARD Q03181 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30574764 1.00 ALDH1A1 (0.40) ALDH1A1MAPTHTTHPGDLMNA
SCHEMBL30574845 0.91 PPARG (0.40) ALDH1A1MAPTHTTHPGDLMNA
SCHEMBL25384316 0.91 PPARG (0.40) ALDH1A1MAPTHTTHPGDLMNA
SCHEMBL30574953 0.84 SMN1; SMN2 (0.39) ALDH1A1MAPTHTTHPGDLMNA
SCHEMBL25385144 0.84 SMN1; SMN2 (0.39) ALDH1A1MAPTHTTHPGDLMNA
SCHEMBL25385433 0.82 MAOB (0.37) ALDH1A1MAPTHTTHPGDLMNA
SCHEMBL30574828 0.82 MAOB (0.37) ALDH1A1MAPTHTTHPGDLMNA
SCHEMBL25385517 0.82 SMPD1 (0.42) ALDH1A1MAPTHTTHPGDLMNA
SCHEMBL30574783 0.82 SMPD1 (0.42) ALDH1A1MAPTHTTHPGDLMNA
SCHEMBL25385232 0.81 PTGS1 (0.48) ALDH1A1HTTHPGDLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115600-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-04-10 — — US disclosed
EP-4486390-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF Terremoto Biosciences, Inc (US) 2025-01-08 — — EP disclosed
WO-2023168291-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-09-07 — — WO disclosed
WO-2023168291-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-09-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115600-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF AKT1, AKT1S1, AKT2 ALDH1A1 4472/4885MAPT 3893/4885HTT 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback